Positron Lymphography: Multimodal, High-Resolution, Dynamic Mapping and Resection of Lymph Nodes After Intradermal Injection of 18F-FDG

Daniel L.J. Thorek1, Diane S. Abour2, Bradley J. Beattie3, Rachel M. Bartlett3, Ruimin Huang1, Pat B. Zanzonico3, and Jan Grimm1,2

1Department of Radiology, Memorial Sloan-Kettering Cancer Center, New York, New York; 2Program in Molecular Pharmacology and Chemistry, Memorial Sloan-Kettering Cancer Center, New York, New York; and 3Department of Medical Physics, Memorial Sloan-Kettering Cancer Center, New York, New York

The lymphatic system plays a critical role in the maintenance of healthy tissues. Its function is an important indicator of the presence and extent of disease. In oncology, metastatic spread to local lymph nodes (LNs) is a strong predictor of poor outcome. Clinical methods for the visualization of LNs involve regional injection and tracking of 99mTc-sulfur colloid (99mTc-SC) along with absorbent dyes. Intraoperatively, these techniques suffer from the requirement of administration of multiple contrast media (99mTc-SC and isosulfan blue), unwieldy γ-probes, and a short effective surgical window for dyes. Preclinically, imaging of transport through the lymphatics is further hindered by the resolution of lymphoscintigraphy and SPECT. We investigated multimodal imaging in animal models using intradermal administration of 18F-FDG for combined diagnostic and intraoperative use. PET visualizes LNs with high sensitivity and resolution and low background. Cerenkov radiation (CR) from 18F-FDG was evaluated to optically guide surgical resection of LNs. Methods: Imaging of 18F-FDG uptake used PET and sensitive luminescent imaging equipment (for CR). Dynamic PET was performed in both sexes and multiple strains (NCr Nude, C57BL/6, and Nu/Nu) of mice. Biodistribution confirmed the uptake of 18F-FDG and was compared with that of 99mTc-SC. Verification of uptake and the ability to use 18F-FDG CR to guide nodal removal were confirmed histologically. Results: Intradermal injection of 18F-FDG clearly revealed lymphatic vessels and LNs by PET. Dynamic imaging revealed rapid and sustained labeling of these structures. Biodistribution of the radiotracer confirmed the active transport of radioglucose in the lymphatics to the local LNs and over time into the general circulation. 18F-FDG also enabled visualization of LNs through CR, even before surgically revealing the site, and guided LN resection. Conclusion: Intradermal 18F-FDG can enhance the preclinical investigation of the lymphatics through dynamic, high-resolution, and quantitative tomographic imaging. Clinically, combined PET/Cerenkov imaging has significant potential as a single-dose, dual-modality tracer for diagnostics (PET/CT) and guided resection of LNs (Cerenkov optical).

Key Words: lymph node mapping; PET/CT; Cerenkov; intraoperative

DOI: 10.2967/jnumed.112.104349
2-dimensional planar information. Tomographic imaging (SPECT) is possible, but it requires long imaging times and has limited resolution. The vital dye may also travel past the sentinel LN. In addition to questions concerning the global supply of $^{99m}$Tc for generators, these limitations have spurred development of replacement (18) or alternative contrast agents exploiting various modalities (3,19).

Here, we demonstrate dual-modality imaging using a single tracer for both lymphatic mapping and guided surgical resection with the ubiquitous PET radiotracer $^{18}$F-FDG. In place of LN accumulation of $^{18}$F-FDG after systemic delivery, injection is performed directly into the rich lymphatic bed of the dermis (20). Similar to $^{99m}$Tc-SC, regional delivery localizes transport of $^{18}$F-FDG through the lymphatic vessels to draining nodes. $^{18}$F-FDG PET/CT clearly delineates the fine vessels and LNs in rodents.

In addition to the low background, inherently quantitative nature, high sensitivity, and high temporal resolution of PET lymphography, the radiotracer itself enables optical guidance to localize nodes through emission of Cerenkov radiation (CR). Produced by high-energy charged particles emitted on radioactive decay ($\beta^+$ for $^{18}$F), the visible-wavelength CR photons from PET isotopes can be acquired using highly sensitive camera equipment (21,22). PET lymphography also allows white-light imaging (standard photography) of the subject, providing anatomic localization for surgical investigations (23). Thus, through a single intradermal injection of $^{18}$F-FDG, a clinically approved and widely available agent, we achieved both exquisite nuclear tomographic lymphatic mapping for preclinical or preoperative investigation and an optical signal to lead intraoperative resection.

MATERIALS AND METHODS

Materials

Iosulfan blue (Lymphazurin) was acquired from Tyco Healthcare Group LP. $^{18}$F-FDG, with a specific activity of more than 41 MBq/μmol (>11 mCi/μmol), was supplied by IBA Molecular, and $^{99m}$Tc-SC was from Cardinal Healthcare. Both tracers had a radiochemical purity greater than 98%. Tracers were acquired through the Radiopharmacy of the Nuclear Medicine Service at Memorial Sloan-Kettering Cancer Center.

Animal Experiments

Animal experiments were in accordance with guidelines from the Institutional Animal Care and Use Committee and with the Guide for the Care and Use of Laboratory Animals from the National Institutes of Health (NIH) (24). All animal procedures were performed under anesthesia by inhalation of a 1%–2% isoflurane–air mixture (Baxter Healthcare). Animals were obtained from either Harlan Laboratories (nu/nu and C57BL/6) or Charles River Laboratories (NCr nude). Male nu/nu mice (12 wk) were used for the representative PET/CT figures, female nu/nu mice (12 wk) for the CR imaging, and male C57BL/6 mice (6–8 wk) for acute biodistribution studies.

Intradermal Injections

$^{18}$F-FDG and $^{99m}$Tc-SC were injected intradermally to study the biodistribution and imaging of the lymphatic system. Hypodermic needles (30-gauge × 1.9 cm [0.75 in], Kendall Monoject; Tyco Healthcare) were used. Dorsal tail injections (~1.2 MBq of $^{18}$F-FDG or 500 kBq of $^{99m}$Tc-SC in a volume of 25–35 μL), the bevel of the needle directly in the dermis, were made at approximately 30 mm from the base of the tail. Constant pressure was applied over 30 s, with care not to disrupt the deep lymphatics or lateral veins.

Small-Animal PET and PET/CT

Mice were imaged prone, using the Focus 120 microPET small-animal scanner (Concorde Microsystems Inc.), with an energy window of 350–700 keV and coincidence-timing window of 6 ns. Acquisition began immediately after intradermal or (for intravenous comparison) retroorbital injection for as long as 60 min.

A custom-built restraint device registered PET and CT image data (25). CT was performed using a microCAT II (ImTek Inc.) scanner operating at 60 kVp and 0.8 mA, with 2-mm aluminum filtration. The fusion montage was arranged in ImageJ (NIH). Three-dimensional rendering was performed using Amira (version 5.0; Visage Imaging GmbH).

PET data were corrected for detector nonuniformity, dead time, random coincidences, and physical decay. List-mode data were binned into histograms at durations of 0.5, 1, and 5 min to study different features of $^{18}$F-FDG transport and uptake. Images were reconstructed by both maximum a priori and 3-dimensional filtered backprojection using a ramp filter with a cutoff frequency equal to the Nyquist frequency into a 128 × 128 × 95 matrix (26). Images were analyzed using ASIPro (Concorde Microsystems Inc.), with window and level settings adjusted for optimal visualization of LNs. To assess flow rates, volumes of interest were drawn around LNs, and time–activity curves were generated.

CR Optical Imaging

After sacrifice, CR images for guided resection were obtained using the IVIS 200 (Caliper Life Sciences). This system uses a cryo-cooled charge-coupled device for high-sensitivity detection of low-intensity sources. Two-minute postmortem exposures were used to identify the presence and distribution of CR from $^{18}$F-FDG in mice. Images were taken after each stage: removal of the dorsal skin, surgical incision to reveal the sacral nodes, and removal of the nodes. Excised tissues were then imaged. To bias a single side for LN draining and provide an internal contralateral reference (of little or no activity), lateral dermal tail injections were made. To visualize distribution differences by route of administration, a separate cohort was given an equal retroorbital dose (~1.2 MBq) of $^{18}$F-FDG, followed by PET/CT and optical imaging ($n = 4$).

Biodistribution Studies

We intradermally injected anesthetized mice with a 3:1 (volume) mixture of $^{18}$F-FDG (or $^{99m}$Tc-SC) and isosulfan blue. Animals were awakened and at the given endpoints sacrificed (10 or 60 min, $n = 5$). Major organs and LNs (including the sacral, inguinal, axial, and caudal nodes) were excised, washed, and wicked of excess water. Background-corrected count-per-minute data of the excised tissues were acquired on an automatic Wizard γ-counter (Perkin Elmer) using an energy window of 400–600 keV for $^{18}$F and 84–163 keV for $^{99m}$Tc. Counts per minute were converted to becquerels using a standard calibration curve, decay-corrected to the time of injection, and reported as percentage of injected dose (%ID) and normalized to mass in grams of tissue (%ID/g).
The weights of many of the LNs in the mouse are on the order of only a few milligrams. As such, special care was taken to obtain accurate weights for in vivo biodistribution studies. An analytic balance (accurate to 1/100th of a milligram) was used for all tissues (Excellence Plus XP; Mettler Toledo). Rather than standard (12 × 75 mm) tubes, 2.0-mL Safe-Lock Eppendorf tubes (Eppendorf North America) were used to minimize dehydration of tissues and minimize weight variation. Individual empty tubes were weighed before necropsy, and all tissues were weighed immediately after γ-counting. To further reduce weighing error, contralateral nodes were pooled. The weights of tissues are included in the supplemental data (Supplemental Fig. 1; available online only at http://jnm.snmjournals.org).

Immunohistochemistry

CR signal was used to guide excision of suspected sacral LNs. In addition to LNs, adjacent (non–Cerenkov luminescent) but visually indistinguishable tissue was excised. Sections (5 μm) were stained for podoplanin and counterstained with hematoxylin. Detailed immunohistologic procedures are included in the supplemental data.

RESULTS

Tracer Selection

Before experimentation with small-molecule radiotracers for multimodal lymphatic imaging, it was necessary to choose a suitable probe. 18F-based tracers have favorable positron emission characteristics for annihilation photon imaging and also produce CR for optical imaging. There is a wide choice of fluorinated compounds, including NaF, 18F-fluo-3′-deoxy-3′-l-fluorothymidine, and 18F-fluorocholine. However, 18F-FDG is the most widely used PET tracer and also the most widely available. In addition to being well tolerated, 18F-FDG can be produced with high specific activity, is routinely available at many sites, and will not interfere with histologic evaluation (staining) of tissue. In tissue, 18F produces on the order of 14 Cerenkov photons per disintegration, making in vivo CR imaging facile at diagnostic doses (27).

18F-FDG PET/CT

PET images demonstrate that the lymphatic vessels and nodes can be visualized after the intradermal administration of 18F-FDG (Fig. 1). Radiotracer distribution and imaging studies were performed on mice after intradermal injection into the tail. The injection site, several centimeters from the base of the tail, drains through lymphatic vessels and nodes that lie medially deep within the animal. This location was chosen on the basis of the tail excision model as described by Boardman et al. (28) and its use for recent lymphoscintigraphic work (29,30).

The combination of PET for high-sensitivity detection of the exogenous tracer and CT for boney structures provides accurate and detailed localization of lymphatic structures. LNs and lymphatic vessels can be clearly identified from a 1-min acquisition at 10 min after injection (Fig. 1).

Initially, the radiotracer is drained from the extracellular space at the injection site through the vessels rostrally. Draining through both lateral lymphatic vessels can be clearly seen on PET images. Flow and retention demarcate the sacral nodes. Further lymphatic draining then leads to distinction of first the caudal and then the mesenteric nodes. All structures are clearly visible, with minimal background signal, because the 18F-FDG at this time point has not diffused or been drained into the vascular system.

Dynamic Imaging

Dynamic imaging using this technique can reveal features of the lymphatic drainage and presence of the nodes and be accomplished over an extended period (Fig. 2). The general distribution of the 18F-FDG initially follows that described above. Over time, the amount of 18F-FDG transported along with lymph into the vascular system, and the likely direct diffusion of the tracer into blood vessels, increases the background activity. Thus, at 60 min, the kidneys, bladder, liver, and heart were often visible.

FIGURE 1. Three-dimensionally rendered positron lymphography images demonstrate high-resolution mapping using intradermal administration of 18F-FDG to a male nu/nu mouse at multiple angles (A–C). Radiotracer is transported from site of injection through lymphatic system, enabling visualization of lymph flow. Delineation of LN draining injection site is clearly distinguished (B; insert is without fused CT). At 10 min after injection, we can identify lymphatic vessels in tail leading first to sacral nodes (1). Tracer then moves proximally to caudal (2) and then mesenteric nodes (3). Gradient arrow indicates direction of flow. Three-dimensionally rendered PET data are generated from weighted average of intensities from all 2-dimensional slices. As such, it is strictly semiquantitative; color bar indicates range of intensities. Max = maximum; Min = minimum.
Imaging frame rates were sufficiently short (Fig. 3A) to reveal the kinetics of initial radiotracer distribution. This high temporal resolution is combined with quantitative read-out of tracer concentration. In addition, the high-frame-rate dynamic and high-resolution lymphography can be given anatomic context through fusion with a CT (or MRI) acquisition. The inherently quantitative information from PET allows for the assessment of lymphatic function through tracer distribution. Over the linear portion of their accumulation, these healthy LNs demonstrate approximately 5.7–6.5 %ID/g values, whereas the most distant mesenteric node displays a lower rate of 1.17 Bq/s of ¹⁸F-FDG (Fig. 3B).

**Acute Biodistribution**

We determined the distribution of the locally administered ¹⁸F-FDG at 2 time points, 10 and 60 min after injection. The biodistribution recapitulates the image data and is presented as both %ID (to convey gross tracer distribution) and %ID/g (to communicate image contrast) (Fig. 4).

Initially, at 10 min, most of the dose is still present at the injection site in the tail (Fig. 4A). Small amounts are present in the blood (mean ± SEM, 0.57 ± 0.21 %ID) and major organs such as the liver (0.98 ± 0.08 %ID). After 1 h, approximately 28.5 ± 8.17 %ID remains in the tail, with a significant amount in the bladder (2.79 ± 1.84 %ID) and active muscle (heart, 1.08 ± 0.20 %ID). At 10 min, the values in the injection site’s draining sacral (0.11 ± 0.02 %ID) and caudal nodes (0.09 ± 0.01 %ID) are an order of magnitude less than those in the larger organs.

The localization of ⁹⁹ᵐTc-SC to sentinel LNs is exceptional as well (Supplemental Fig. 3). However, in comparison to ¹⁸F-FDG, the ⁹⁹ᵐTc-SC moves more slowly from the injection site. At 10 and 60 min after injection, 80.79 ± 1.52 and 79.83 ± 0.65 %ID remain in the tail, respectively. This reflects the fact that little of the colloidal tracer is able to drain from the injection site. For ¹⁸F-FDG, at 10 and 60 min, these values are 43.85 ± 0.92 and 28.59 ± 8.17 %ID, respectively. Here, clearance occurs through processes that include lymph transport and diffusion of the small molecule. The ⁹⁹ᵐTc-SC particles also localize more slowly to the nodes; an increase in %ID is seen from 10 to 60 min, the opposite of the case for ¹⁸F-FDG. This timing is concordant with the significantly larger diameter and mass of the colloid, favoring faster transport of ¹⁸F-FDG.

After normalization by the mass of the tissues to yield %ID/g values, the high node–to–other tissue values replicate the clear imaging delineation of the LNs (Fig. 4B). Active transport of the radiotracer from the dermal tail injection site through the lymphatic vessels and to the draining nodes presents highly specific anatomic localization of the tracer. The sacral nodes exhibit 183 ± 79.0 %ID/g (mean ± SEM) at 10 min after injection. Nodes that are not in the draining pathway of the tail injection site (e.g., the axillary nodes [0.77 ± 0.392 %ID/g]) contain activity that is equivalent to the body background.

The exquisite delineation of the nodes from the PET acquisitions is a result of the high node-to-muscle and node-to-blood ratios (Fig. 5). These compartments commonly confound systemic ¹⁸F-FDG imaging, particularly in attempts to image lymphatic structures at early time points. However, the anatomic specificity of the intradermal injection leads to localization of the tracer in the draining nodes, with minimal blood or muscle extravasation. The ratio of LN to muscle decreases with time but is still high at 60 min, and the LN-to-blood ratio increases as free ¹⁸F-FDG is excreted. This finding is significant because the biodistribution studies were performed on animals that were not anesthetized; therefore, no effort was made to limit metabolic uptake of the tracer in active muscles. No contrast enhancement is seen in LNs that are not in the drainage path from the injection site (e.g., axillary lymphatics).

**Cerenkov-Guided Intraoperative Imaging**

The transit and accumulation of the ¹⁸F-FDG at the sacral nodes provides sufficient CR to guide surgical intervention and resection of LNs (Fig. 6). The intradermal injection isolates the ¹⁸F-FDG to the draining lymphatic channels and their associated LNs. The sacral node can be seen after removal of the skin (i.e., in an intraoperative setting), before any
further surgical exposure (PET acquisition is included as Supplemental Fig. 2). The resected node continues to generate CR after excision and therefore provides immediate verification of the lymphatic nature of removed tissue.

In comparison, CR imaging reveals that the retroorbital injection of 18F-FDG results in accumulation in the kidneys and liver, rather than at any specific nodal sites. The sacral node identified using intradermal injection is not visible in the intravenously injected subject, even after the node is revealed by surgical incision. The optical approach enables detection of sites of radiotracer uptake and white-light anatomic localization using the same camera. Previously, 99mTc-SC has been applied as a single tracer for both lymphoscintigraphy (or SPECT) and intraoperative guidance through use of operating-room γ-cameras and handheld γ-probes. However, adoption of these technologies has been limited by lack of anatomic reference. Intradermal 18F-FDG provides high spatial resolution for optical imaging to guide resection of the small nodes in addition to the option of high-resolution preoperative PET.

Immunohistochemistry
The excised tissues were validated as LNs using immunohistochemistry (Fig. 6D). The hematoxylin and eosin counterstain revealed the high cellular density indicative of lymphatic tissue. Podoplanin is a specific marker for lymphatic tissues (31–33), and staining for podoplanin confirms the presence of lymphatic endothelium in resected tissues.

DISCUSSION
Here, we have described the intradermal application of 18F-FDG for the dual purposes of mapping the lymphatic vessels and nodes using PET and for Cerenkov-guided surgery. Systemic intravenous injection of 18F-FDG for lymphographic examination has been explored in a host of studies. These studies often observe increased uptake at inflamed and invaded nodal sites. Clinically, the increased uptake indicates and helps identify disease. However, intravenous administration results in a substantial background signal, with renal clearance of the tracer required before any useful acquisition, abrogating the ability to conduct early-time-point or dynamic studies. In addition, imaging of nodes is difficult in regions of the pelvis (relevant for diseases such as prostate and cervical cancer) because of bladder uptake. The intradermal approach described here avoids the systemic and vascular distribution of the tracer at early time points, and the lymphatics are still clearly visible as late as 1 h after injection. This visibility allows for mapping of the lymphatic system directly through positron energy (Cerenkov) and annihilation photon (PET) events.

Intradermal injection of radiotracers leading to accumulation in the draining LN has previously been observed, either by accident or by design (34,35). However, macromolecules or nanoparticles have been the preferred formulation for lymph-mapping agents in use or in development (36). The rationale has been that such materials will avoid diffusion into the vascular compartment and stay at a draining node.

This work shows that an approved small molecule is well suited to this purpose. In fact, this approach had been previously attempted (in the context of a biodistribution study) and dismissed, because only regional nodes could be detected (35). However, technologic advancements in the imaging sciences (namely the development of PET/CT, MRI/PET, greater-resolution PET, and Cerenkov imaging) now enable...
this type of imaging as a viable, powerful, and facile technique for efficient and sensitive lymphatic mapping localized with anatomic information. Our results demonstrate that 18F-FDG, the most widely used and readily available PET radiopharmaceutical, enables exquisite lymphography and has intraoperative potential through Cerenkov imaging. On the basis of cost, effectiveness, and availability, 99mTc-SC is an excellent agent. However, intradermal administration of an 18F-labeled small molecule results in several advantages. Initially, the tracer is confined to the lymphatic system compartment. As demonstrated with dynamic imaging, approximately 40 min are required for the tracer to become present in other tissues at comparative levels. The use of a positron emitter, 18F, provides high-resolution tomographic and quantitative distribution information. These features, in conjunction with the anatomic localization provided by CT, result in finely detailed images of the lymphatic system. 18F-FDG also has favorable distribution characteristics. Unlike 99mTc-SC, the small-molecule radioglucose clears from the injection site fairly quickly, thus avoiding the obscuring of features at or near the injection. A clear advantage of the small-molecule approach for patient management is that draining nodes located outside the immediate (or for prostate, routinely dissected) area can be tomographically localized by PET. The resolution and sensitivity of PET enable the discernment of both the lymphatic vessels and the LN with great detail in deep tissue. This ability has important implications for preclinical investigation. Despite its importance, the lymphatic system remains poorly understood in part because of a lack of imaging tools. The positron lymphography approach presented here can aid analysis of rodent models (i.e., that possess lymphatic structures many times smaller than those of primates) and applies to LN drainage from appendages such as the tail (Figs. 1 and 2) and feet (Supplemental Fig. 5). The LNs as visualized by PET appear larger than they are, because the dimensions of these structures are well below the resolution (full width at half maximum) of small-animal PET. Lymphoscintigraphy and SPECT with 99mTc-SC have relatively poorer resolving power, and near-infrared approaches have limited depth penetration in contrast to the whole-body method using 18F-FDG.
Positron decay produces CR that is detectable by sensitive cameras. Cerenkov-guided surgical resection of LNs would be an advance over current techniques in that it requires the administration of a single, nontoxic agent to localize nodes. $^{99m}$Tc is a $\gamma$-emitter with virtually no positron emission and does not generate CR.

CR from nodal uptake of $^{18}$F-FDG was used to guide resection of sacral nodes that are virtually undetectable without alternative contrast (vital dyes). However, the use of dyes (isosulfan blue) is hampered by washout from the node of interest and potential allergic reaction (39). As seen from the dynamic imaging (Fig. 2), the transit of $^{18}$F-FDG to LNs with minimal background is sustained over a sufficiently long period (at least 1 h) to potentially facilitate intraoperative events and the short half-life, $^{18}$F-FDG can be repeatedly administered for lymphatic delineation in a research or surgical lymph mapping study.

CONCLUSION

The lymphatic vasculature plays a critical role in maintaining the body’s fluid balance. Aberrant lymph function and lymphadenopathy are significant indicators of the presence and extent of disease. Approaches for visualizing these events include $^{99m}$Tc-SC lymphoscintigraphy, SPECT, absorbent optical imaging, or albumin-bound near-infrared fluorescence imaging (16). However, scintigraphic and SPECT approaches have limited resolution and anatomic localization, whereas fluorescent studies are nonquantitative, tissue depth–dependent, and hampered by a limited choice of approved fluorophores (namely, indocyanine green). The ability to image the lymphatics tomographically at the detail of its fine structure, with high-sensitivity and in a quantitative regime, may greatly enhance the study of these systems.

We have shown that the common PET tracer $^{18}$F-FDG is localized in the LNs draining from an intradermal injection. The high sensitivity and low background provide excellent discrimination for localizing LNs and studying lymphatic vessel transport. Dynamic imaging can be performed with this easily obtained and approved tracer. Importantly, through imaging developments to capture CR from positron emissions, it is also possible to optically detect nodal uptake of this radiotracer in vivo, enabling dual-modality imaging of an approved tracer for preoperative tomographic whole-body imaging along with intraoperative planar anatomic guidance using CR, $\gamma$-probes, and positron detectors. We suggest that the use of a widely used PET tracer, through an alternative delivery mechanism, presents an important preclinical and clinical advance toward greater understanding of and care for diseases involving the lymphatic system.

H&E = hematoxylin and eosin, control hamster IgG, and podoplanin. The stromal region of node is indicated by dense hematoxylin and eosin and positive podoplanin staining. Dotted line indicates region of magnification (included as Supplemental Fig. 4). Scale bar, 1 mm.

FIGURE 6. Cerenkov-guided surgical resection of $^{18}$F-FDG–bearing LN, 10 min after injection, with surgical validation. (A) Lateral-tail intradermal injection yields greater uptake in 1 sacral node, seen with just skin removed. PET image is included as Supplemental Figure 2. (B) CR guides resection of node, magnified in inset. (C) Systemic administration of $^{18}$F-FDG (retroorbital injection) does not enable identification of nodes, even after surgical exposure. Signal from renal clearance can be seen. (D) Immunohistologic verification of Cerenkov-guided excised tissues. Resected node as indicated by CR, along with surrounding connective tissue, was stained with
DISCLOSURE STATEMENT

The costs of publication of this article were defrayed in part by the payment of page charges. Therefore, and solely to indicate this fact, this article is hereby marked “advertisement” in accordance with 18 USC section 1734.

ACKNOWLEDGMENTS

We thank the staff of the Radiopharmacy at MSKCC. We give special thanks to Dr. Steve Larson for his input and Drs. Bill Strauss, Michael McDevitt, Jason Lewis, Kishore Pillarsety, and Mesruh Turkekul. This study was supported in part through the R2ST Molecular Imaging Fellowship: Molecular Imaging Training in Oncology (5R25CA096945-07); the 2011 SNM Postdoctoral Molecular Imaging Scholar Program; the Louis V. Gerstner Young Investigator Award; ARRA 73950; NIH grants 1R01EB014944-01, R24 CA83084, and P30 CA08748; and the MCCF. No other potential conflict of interest relevant to this article was reported.

REFERENCES